Takamori, Shinkichi
Shimokawa, Mototsugu
Matsubara, Taichi
Haratake, Naoki
Toyozawa, Ryo
Miura, Naoko
Yamaguchi, Masafumi
Seto, Takashi
Tagawa, Tetsuzo
Okamoto, Tatsuro
Takenoyama, Mitsuhiro
Maehara, Yoshihiko
Mori, Masaki
Article History
Received: 7 April 2020
Accepted: 19 June 2020
First Online: 16 July 2020
Disclosures
: Takashi Seto received grants and personal fees from AstraZeneca, grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Daiichi Sankyo, grants and personal fees from Eli Lilly Japan, grants and personal fees from MSD, grants and personal fees from Nippon Boehringer Ingelheim, grants and personal fees from Novartis Pharma, grants and personal fees from Pfizer Japan, grants and personal fees from Takeda Pharmaceutical, personal fees from Astellas Pharma, personal fees from Bristol-Myers Squibb, personal fees from Kyowa Hakko Kirin, personal fees from Ono Pharmaceutical, personal fees from Taiho Pharmaceutical, personal fees from Thermo Fisher Scientific, grants from Abbvie, grants from Bayer Yakuhin, grants from Kissei Pharmaceutical, grants from LOXO Oncology, grants from Merck Serono, and personal fees from Precision Medicine Asia Co. Ltd., outside the submitted work. Tetsuzo tagawa received grants from Chugai Pharmaceutical and Roche Diagnostics. Masaki Mori received grants from Chugai Pharmaceutical. All the other authors declare no conflicts of interest.